Marqus Susan, Pirogova Elena, Piva Terrence J
School of Engineering, RMIT University, Bundoora, VIC, 3083, Australia.
School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, 3083, Australia.
J Biomed Sci. 2017 Mar 21;24(1):21. doi: 10.1186/s12929-017-0328-x.
Cancer along with cardiovascular disease are the main causes of death in the industrialised countries around the World. Conventional cancer treatments are losing their therapeutic uses due to drug resistance, lack of tumour selectivity and solubility and as such there is a need to develop new therapeutic agents. Therapeutic peptides are a promising and a novel approach to treat many diseases including cancer. They have several advantages over proteins or antibodies: as they are (a) easy to synthesise, (b) have a high target specificity and selectivity and (c) have low toxicity. Therapeutic peptides do have some significant drawbacks related to their stability and short half-life. In this review, strategies used to overcome peptide limitations and to enhance their therapeutic effect will be compared. The use of short cell permeable peptides that interfere and inhibit protein-protein interactions will also be evaluated.
癌症与心血管疾病是全球工业化国家的主要死因。由于耐药性、缺乏肿瘤选择性和溶解性，传统的癌症治疗方法正在失去其治疗用途，因此需要开发新的治疗药物。治疗性肽是治疗包括癌症在内的多种疾病的一种有前景的新方法。与蛋白质或抗体相比，它们有几个优点：（a）易于合成，（b）具有高靶向特异性和选择性，（c）毒性低。治疗性肽在稳定性和半衰期短方面确实存在一些重大缺点。在这篇综述中，将比较用于克服肽的局限性并增强其治疗效果的策略。干扰和抑制蛋白质-蛋白质相互作用的短细胞穿透肽的应用也将得到评估。
